STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Investor Presentation (August 2021)

23 slides from STRATA Skin Sciences's investor presentation, Aug 25, 2021

  1. Slide 1: Driving Value to Dermatology Partners Matching Patients with Clinics

    Investor Presentation December 2020 Investor Presentation August 2021 Driving Value to Dermatology Partners Matching Patients with Clinics

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,”

  3. Slide 3: Large Market Opportunity

    Large Market Opportunity 31 Million lives in the U.S.: $6 Billion annual revenue1XTRAC is the market leader in excimer laser therapyReimbursement: 3 unique CPT codes Q3 Acquisition of the U.S. Pharos dermatology business of Ra Medical – Positions Company as predominant provider of excimer laser trea

  4. Slide 4: Acquired the U.S. Pharos Dermatology Business of Ra Medical Systems

    Acquired the U.S. Pharos Dermatology Business of Ra Medical Systems 4 Provides STRATA with the opportunity to market its full business solution to Ra Medical’s existing customer base of 400 dermatology practices Delivers added long-term recurring revenue growth potential and prospective customer bas

  5. Slide 5: Large Unmet Need in Common and Chronic Dermatologic Conditions

    Large Unmet Need in Common and Chronic Dermatologic Conditions 5 ATOPIC DERMATITIS PSORIASIS VITILIGO PSORIASIS: Autoimmune disease that causes the skin to regenerate faster than normal; characterized by red, itchy scaly patches (65% Mild; 25% Moderate; 10% Severe)~8 Million patients in the U.S.3 VI

  6. Slide 6: Treatment Options Addressing Chronic Dermatologic Conditions

    Treatment Options Addressing Chronic Dermatologic Conditions6 6 XTRAC NB-UVB* Topical Steroids Non-biologic Systemics Biologics Approximate Costs ($) Cost competitive 1K-3K 3K-9K 1K -7K 1K 32K-68K Clinical Impact Better clinical outcomes (PASI%75) 92% 71% 75% 48% 50-70% Speed of Onset (in weeks) Ver

  7. Slide 7: XTRAC: A True Partnership – A Complete Business Solution

    XTRAC: A True Partnership – A Complete Business Solution 7 Clinical Support Reimbursement Support Call Center Support Field Service Support Consumables and Parts Laser Upgrades Co-pay Assistance DTC Marketing

  8. Slide 8: Excimer Laser Technology for Dermatology Indications

    Excimer Laser Technology for Dermatology Indications 8 #1 Targeted Laser Therapy Prescribed by Dermatologists FDA approved + established CPT codes150+ Peer-reviewed clinical studies2000+ device installed base, WW20+ million treatments performed WW Best-in-class Excimer TREATMENT

  9. Slide 9: Key Priority: Driving Commercial Execution

    Key Priority: Driving Commercial Execution 9 Increase investment in DTC marketing Re-engage with high-volume accounts Target current, non-revenue partners Increase marketing to drive awareness among derms Historical trends show positive correlation between increased DTC investment and revenue growth

  10. Slide 10: XTRAC: Psoriasis

    10 After 4 tx After 2 tx Baseline Clinical Protocol – 6.2 treatments to PASI 75 Beam of UVB light applied to the affected area PASI - A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis XT

  11. Slide 11: XTRAC: Vitiligo

    XTRAC: Vitiligo 11 Beam of UVB light applied to the affected area XTRAC: The solution for Vitiligo Results in re-pigmentation UVB light reduces the immune system’s attack on the melanocytes Simple, safe, effective + long-lastingExcimer laser Baseline After 18 tx After 29 tx

  12. Slide 12: Domestic XTRAC Revenue Funnel

    Domestic XTRAC Revenue Funnel 12 REOCCURRENCE DTC ADVERTISING ASSIGNING A DOCTOR PARTNER PATIENTAPPOINTMENT TREATMENT WIN-WIN-WIN DOCTOR + PATIENT + PAYER INTEREST CREATION IN-HOUSE CALL CENTER INSURANCE ADVOCACY VERIFY XTRACTREATMENT VERIFY APPOINTMENTPrescription of Treatment 1. DTC expands Patien

  13. Slide 13: Growing Installed Base Leads to Recurring Revenue Model

    Growing Installed Base Leads to Recurring Revenue Model 13 01/01/18 +92 -99 -7 net Systems 12/31/18 1/01/19 12/31/19 +160 -76 +84 net Systems 12/31/20 01/01/20 +106 -76 +30 net Systems Average Revenue/System $7,055 $7,571 $5,145 Expand Installed Base +Remove Underperforming Systems Utilization Recur

  14. Slide 14: Domestic Installed Base Growth Drivers

    Domestic Installed Base Growth Drivers 832 1,962 251* XTRAC Partners Group Clinics As of 12/31/20 As of 12/31/19 1,962 clinics owned by 49 roll-up groups at 12/30/2020251 (13%) of which are XTRAC partners at 12/30/2020Signed strategic expansion agreements with major groupsIncreased from 251 at 12/30

  15. Slide 15: Domestic Market: Installed Base – Sales and Service Engine

    Domestic Market: Installed Base – Sales and Service Engine Overview848 Partner XTRAC Clinics160+ Sold XTRAC4 Regions30 Sales Territories2 National Account Managers15 Field Service TechsIn-House Call Center to Qualify LeadsOnly One Competitor in U.S. 15 Territories color coded

  16. Slide 16: International Market: Installed Base Strategic Growth Targets

    International Market: Installed Base Strategic Growth TargetsCurrent Markets: China, Japan, Saudi Arabia, S. KoreaInsurance covered in most marketsUsage/device higher than domestic market1,300 OUS devices sold and in servicePlacement recurring revenue model agreements:Executed for South Korea (July

  17. Slide 17: Partner Academic Institutions

    Partner Academic Institutions 17

  18. Slide 18: Sample Studies from 150+ Clinical Studies

    Multicenter Psoriasis Study7 Scalp Study9 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or bet

  19. Slide 19: Financial Metrics

    Financial Metrics 19 * Total recurring revenue over total installed base** Company estimates not provided Unaudited quarterly results * See press release dated August 16, 2021 for definitions of non-GAAP measures

  20. Slide 20: STRATA Key Investment Takeaways

    STRATA Key Investment Takeaways 20 Differentiated Therapy providing a Win-Win-Win for Patients + Clinics + Payers Addressing a Large Unmet Need + Growing Market +Platform for inorganic growth Proven Business Model to Expand + Achieve Sustainable Growth

  21. Slide 21: Thank You

    Investor Presentation December 2020 Thank You

  22. Slide 22: Appendix

    Investor Presentation December 2020 Appendix

  23. Slide 23: Footnotes

    Footnotes Company estimatesHistorical phototherapy utilization. Trend in phototherapy utilization among Medicare beneficiaries by billing code across all providers, 2000 to 2015. HCPCS, Healthcare Common Procedure Coding System; PUVA, psoralen plus ultraviolet A; UVB, ultraviolet BNational Eczema As

STRATA Skin Sciences — Investor Presentation (August 2021) on 6ix